C ytochrome P450 epoxygenases metabolize arachidonic acid (AA) to epoxyeicosatrienoic acids (EETs), which are converted to dihydroxyeicosatrienoic acids (DHETs) by epoxide hydrolases. 1 These P450-derived eicosanoids possess potent biological effects in extracardiac tissues. 1 In contrast, less is known about P450 epoxygenases and their eicosanoid products in the heart. Multiple P450s are expressed in heart tissue. [1] [2] [3] Among these, CYP2J2 is unique in that it is primarily expressed in the heart, abundant in cardiomyocytes, and active in the biosynthesis of EETs. 3, 4 The recent identification of a functionally relevant polymorphism in the CYP2J2 gene that is associated with cardiovascular disease risk in humans supports the clinical relevance of this pathway. 5, 6 Increased EET biosynthesis in stenosed coronary arteries and during cardiac ischemia/reperfusion suggests the hypothesis that EETs may serve a protective mechanism in the ischemic myocardium. 7, 8 Both EETs and DHETs have potent vasodilatory effects in the coronary circulation. 9, 10 Indeed, the P450 epoxygenase metabolites are leading candidates for endothelial-derived hyperpolarizing factor, the nitric oxide synthase-and cyclooxygenase-independent vasodilator that hyperpolarizes vascular smooth muscle cells by opening Ca 2ϩ -activated K ϩ channels. 9, 10 The EETs have been shown to activate p42/p44 MAPK in coronary vascular endothelial and smooth muscle cells. 11, 12 The EETs also directly affect cardiomyocyte function. EETs shorten the cardiac action potential, inhibit cardiac Na ϩ channels, and activate cardiac K ATP . [13] [14] [15] In general, coronary vasodilation, inhibition of Na ϩ channels, activation of K ATP , shortening of the action potential, and activation of p42/p44 MAPK confer cardioprotection during ischemia/reperfusion; however, studies on the influence of P450 epoxygenase products on postischemic recovery of heart contractile function have produced conflicting re-sults. 3, 16, 17 Moreover, CYP2J2 metabolizes linoleic acid (LA) to epoxyoctadecenoic acids (EpOMEs), which depress cardiac function. 18, 19 To examine the cardiac effects of P450-derived eicosanoids under basal conditions and during ischemia/reperfusion, we used the cardiomyocyte-specific ␣-myosin heavy chain (␣MHC) promoter to overexpress the human CYP2J2 cDNA in a transgenic model. CYP2J2 Tr mice have normal heart anatomy and basal contractile function, but exhibit improved postischemic recovery of left ventricular function. Moreover, our data suggest that the mechanism for this cardioprotection by CYP2J2 metabolites involves activation of mitoK ATP and p42/p44 MAPK.
Materials and Methods
For an expanded Materials and Method section, see the online data supplement available at http://circres.ahajournals.org.
Transgenic Mice
The CYP2J2 cDNA (GenBank U37143) was cloned into the vector pBS-␣MHC-hGH, a generous gift from Dr Jeffrey Robbins (University of Cincinnati, Ohio). This vector contains the ␣MHC promoter to drive cardiomyocyte-specific expression of the transgene and human growth hormone (hGH)/polyA sequences to enhance transgene mRNA stability. 20 The linearized transgene was microinjected into pronuclei of single cell C57BL/6NTac mouse embryos (Taconic, Germantown, NY), which were implanted into pseudopregnant mice. Founders were identified by a combination of PCR and Southern blotting of genomic DNAs. 6 All studies were approved by the NIEHS Animal Care and Use Committee.
Northern Analysis, Immunoblotting, and Immunohistochemistry
Northern blotting was performed as described. 4 Polyclonal antibodies against recombinant human CYP2J2 (anti-CYP2J2rec) and against CYP2J2-specific peptides HMDQNFGNRPVTPMR (antiCYP2J2pep1) and RESMPYTNAVIHEVQRMGNIIPLN (antiCYP2J2pep3) were prepared as described. 4, 6 Immunoblotting was performed as described. 6 Control studies showed that antiCYP2J2pep1 and anti-CYP2J2pep3 are immunospecific for CYP2J2, whereas anti-CYP2J2rec cross-reacts with mouse CYP2J isoforms. Immunohistochemical staining of formalin-fixed, paraffinembedded heart sections was performed as described. 3 
Fatty Acid Metabolism
Heart microsomal fractions were incubated with [1- 14 C]AA and products were analyzed by HPLC as described. 4, 6 Epoxygenase activity was calculated as the rate of EETsϩDHETs produced per mg protein/min. Cardiomyocytes were isolated from neonatal CYP2J2 Tr and WT hearts as described 21 and cultured on 1% gelatin-coated plates in Dulbecco modified Eagle's medium containing 10% fetal bovine serum. Cardiomyocyte cell culture media was analyzed for epoxy and dihydroxy fatty acid derivatives of AA and LA using established HPLC/MS/MS methods. 22 
Transthoracic Echocardiography and Assessment of Heart Anatomy
Two-dimensional M-mode echocardiography was performed using an HDI-5000 echocardiograph as described. 23 CYP2J2 Tr mice (25 to 30 g, 4 to 6 months) and WT littermate controls were then euthanized, and hearts removed, dissected, weighed, fixed in 10% neutral buffered formalin, embedded in paraffin, sectioned, and stained with hematoxylin/eosin for histological examination.
Isolated-Perfused Hearts
Hearts were perfused in the Langendorff mode as described. 24 Hearts from all four CYP2J2 Tr lines and age/sex-matched WT littermate controls were perfused in a retrograde fashion at constant pressure (90 cmH 2 O) with continuously aerated (95% O 2 /5% CO 2 ) KrebsHenseleit buffer at 37°C. Hearts were perfused for 40 minutes (stabilization), then subjected to 20 minutes global no-flow ischemia, followed by 40 minutes reperfusion. For some experiments, hearts were stabilized for 20 minutes, then perfused with either the selective P450 epoxygenase inhibitor MS-PPOH (50 mol/L), 11,12-EET (1 mol/L), the sarcolemmal K ATP (sarcK ATP ) and mitoK ATP inhibitor GLIB (20 mol/L), the selective mitoK ATP inhibitor 5-HD (100 mol/L), the K ATP opener pinacidil (PIN, 100 mol/L) or vehicle for 20 minutes, then subjected to 20 minutes ischemia and 40 minutes reperfusion. In other experiments, the MEK inhibitor PD98059 (10 mol/L) or vehicle was administered during the 40 minutes reperfusion period. Recovery of contractile function was taken as LVDP at 40 minutes reperfusion expressed as a percentage of preischemic LVDP.
Flavoprotein Fluorescence
Cardiomyocytes were isolated from hearts of adult CYP2J2 Tr and WT mice and plated onto Laminin-coated dishes in M199 media as described. 16 Endogenous flavoprotein fluorescence was used as a marker of mitoK ATP activity. 25, 26 Fluorescence was excited by the 488-nm line of a krypton-argon laser, emission was recorded at 568 nm, and confocal images were taken on a Model 410 laser scanning confocal microscope (Carl Zeiss Inc, Thornwood, NY). Emitted fluorescence was assessed in CYP2J2 Tr and WT cardiomyocytes at baseline and after treatment with sodium cyanide (NaCN, 2 mmol/ L), 2,4-dinitrophenol (DNP, 0.2 mmol/L), PIN (100 mol/L), or 5-HD (100 mol/L). Measurements were taken from 55 to 60 cells from 4 to 7 individual animals of each genotype and intensities were quantified relative to background levels. In some experiments, changes in fluorescence were recorded in WT cardiomyocytes treated with either 14,15-EET (1 to 5 mol/L), 11,12-EET (1 mol/ L), or vehicle. Changes in fluorescence were expressed as percentage change relative to baseline levels.
p42/p44 MAPK Expression and Activation
The expression of total and phospho-p42/p44 MAPK was determined in hearts at different times during the ischemia/reperfusion protocol. Individual hearts from either CYP2J2 Tr or WT mice were frozen after 20 minutes of perfusion, 10 minutes or 20 minutes of ischemia, and 10 minutes or 40 minutes of reperfusion. Protein from the 10 000g supernatant of individual hearts was resolved on SDS-polyacrylamide gels, transferred to nitrocellulose membranes and immunoblotted with antibodies to p42/p44 MAPK, phosphop42/p44 MAPK (Cell Signaling Technology, Inc), or actin C-11 (Santa Cruz Biotechnology). Relative band intensities, expressed in arbitrary units of phospho-p42/p44 MAPK to total p42/p44 MAPK, were assessed by densitometry using a ChemiImager 4000 System (Alpha Innotech Corp).
Statistical Analysis
Data were analyzed by investigators who were blinded to genotype and treatment group assignment. Values are expressed as meanϮSE. Data were analyzed by ANOVA or Student's t test using SYSTAT software (SYSTAT Inc.). Values were considered significantly different if PϽ0.05.
Results

Development and Initial Characterization of Transgenic Mice
Six germline founder mice were generated by microinjection of the transgenic construct (Figure 1a (Figure 1g ). Although there was some interanimal variability in the magnitude of CYP2J2 overexpression, we did not observe any consistent or significant differences in CYP2J2 levels among transgenic offspring from founder lines Tr2, Tr3, Tr5, and Tr7. Therefore, all subsequent studies used heterozygous CYP2J2 Tr progeny of each of these overexpressing lines and age/sex-matched WT littermate controls.
Heart Anatomy and Baseline Function
The Table summarizes anatomic and functional characteristics in CYP2J2 Tr and WT hearts. There were no significant differences between the two groups in heart or individual chamber weights, echocardiographic dimensions or fractional shortening, heart rate, or hemodynamic parameters under basal conditions. Histological assessment of hematoxylin/eosin-stained sections revealed no pathology. These data indicate that CYP2J2 Tr hearts are anatomically and functionally normal at baseline.
Fatty Acid Metabolism
Microsomes from CYP2J2 Tr hearts exhibited Ϸ3-fold higher AA epoxygenase activity than microsomes from WT hearts (Figure 2a ), indicating increased capacity for cardiac EET biosynthesis with CYP2J2 overexpression and confirming that the overexpressed P450 was catalytically active. To further assess fatty acid metabolism from endogenous lipid pools, we measured levels of 11 different P450 epoxygenase-derived products of AA and LA in culture media from isolated CYP2J2 Tr and WT cardiomyocytes by HPLC/MS/ MS. EETs levels in culture media were generally low and were not significantly different between CYP2J2 Tr and WT cardiomyocytes ( Figure 2b ). Importantly, CYP2J2 Tr cardiomyocytes released significantly more 14,15-DHET, 11,12-DHET, and 8,9-DHET (stable metabolites of 14,15-EET, 11,12-EET, and 8,9-EET) into culture media than did WT cardiomyocytes ( Figure 2b ). These data are consistent with the known regiochemistry of olefin epoxidation by CYP2J2 and the presence of an active epoxide hydrolase in mouse cardiomyocytes. 4 In contrast, there were no significant differences between the two genotypes in the levels of EpOMEs or dihydroxyoctadecenoic acids (DHOMEs) released into culture media (Figure 2b ).
Cardiac Performance After Ischemia/Reperfusion in Perfused Hearts
CYP2J2 Tr hearts had normal baseline contractile function, measured either as LVDP (Figure 3a ; Table) or rate-pressure product (RPPϭLVDPϫHR) (Figure 3b ; Table) . Compared with WT, CYP2J2 Tr isolated-perfused hearts had significantly improved postischemic recovery of left ventricular function. The improved function was evident within 10 minutes of reperfusion and persisted throughout the recovery period (Figure 3a) . At 40 minutes reflow, LVDP recovery was significantly higher in CYP2J2 Tr (37Ϯ4%) versus WT hearts (22Ϯ2%, PϽ0.01) (Figure 3a ; Table) . Similarly, RPP recovered significantly better in CY2J2 Tr versus WT hearts (33Ϯ4% versus 18Ϯ3%, respectively; PϽ0.005) (Figure 3b ; Table) . Consistent with the improved postischemic contractile function, left ventricular end-diastolic pressure (LVEDP) at 40 minutes reflow was significantly lower in CYP2J2 Tr (62Ϯ6 cmH 2 Body and heart weights were determined using an analytical balance; dimensions and percent fractional shortening were assessed by transthoracic echocardiography in conscious mice; hemodynamic parameters were measured in isolated-perfused hearts. There were no significant differences in any of these parameters between CYP2J2 Tr and WT mice at baseline. Significant differences were observed in hemodynamic parameters after 20 minutes ischemia and 40 minutes reperfusion (R40). *PϽ0.05 vs WT.
HR indicates heart rate; LVDP, left ventricular developed pressure; LVEDP, left ventricular end-diastolic pressure.
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the four overexpressing lines. When analyzed separately by line, postischemic LVDP recovery in WT and CYP2J2 Tr littermates was 25Ϯ5% and 46Ϯ4% from line Tr2 (Pϭ0.01), 23Ϯ5% and 38Ϯ5% from line Tr3 (Pϭ0.04), 20Ϯ3% and 31Ϯ3% from line Tr5 (Pϭ0.05), and 17Ϯ4% and 35Ϯ6% from line Tr7 (Pϭ0.05).
To determine whether the effects of CYP2J2 overexpression were mediated by a P450 epoxygenase metabolite, we conducted experiments in the presence of MS-PPOH. This epoxygenase inhibitor caused a small but significant reduction in postischemic recovery in WT mice; recovery of LVDP at 40 minutes reflow was 23Ϯ2% in the absence of MS-PPOH and 13Ϯ4% in the presence of MS-PPOH (PϽ0.005) (Figure 3c ). Importantly, MS-PPOH completely abolished the improved postischemic recovery in CYP2J2 Tr mice; recovery of the LVDP at 40 minutes reflow was 37Ϯ3% in the absence of MS-PPOH and 14Ϯ3% in the presence of MS-PPOH (PϽ0.005) (Figure 3c ). Thus, percent LVDP recovery was comparable in the two genotypes after treatment with MS-PPOH. Interestingly, perfusion with physiologically relevant concentrations of 11,12-EET improved postischemic recovery in WT hearts (Figure 3d ). Together, these data suggest that the cardioprotective effects of CYP2J2 overexpression are mediated by a P450 epoxygenase metabolite.
Role of K ATP in Postischemic Functional Recovery
To determine whether K ATP was involved in CYP2J2-mediated cardioprotection, we conducted experiments in the presence of the sarcK ATP and mitoK ATP inhibitor GLIB or the selective mitoK ATP inhibitor 5-HD. Neither GLIB nor 5-HD had a significant effect on baseline LVDP. Perfusion with either GLIB or 5-HD for 20 minutes before ischemia resulted in a small but significant reduction in postischemic LVDP recovery in WT hearts (Figure 4) . Interestingly, both inhibitors completely abolished the improved postischemic functional recovery in CYP2J2 Tr hearts (Figure 4) . Thus, percent LVDP recovery at 40 minutes reperfusion was comparable in the two genotypes after treatment with either GLIB or 5-HD (Figure 4) . Moreover, the K ATP opener PIN improved postischemic functional recovery to a greater degree in WT compared with CYP2J2 Tr hearts such that percent LVDP recovery was comparable in the two genotypes after treatment with PIN ( Figure 4 ). These data suggest the involvement of K ATP in the cardioprotective effect of CYP2J2 overexpression.
Endogenous Flavoprotein Fluorescence
To further investigate the effect of CYP2J2 overexpression on mitoK ATP activity, we measured endogenous flavoprotein fluorescence, an index of mitochondrial redox state, 25, 26 in (Figure 5a) , PIN, NaCN, and DNP (data not shown) confirmed that the emitted fluorescence correlated well with changes in mitochondrial redox status and mitoK ATP activity. We also examined the effect of CYP2J2-derived metabolites on flavoprotein fluorescence in WT cardiomyocytes. Application of 14,15-EET (1 to 5 mol/L), the major CYP2J2 product, resulted in a dose-dependent increase in flavoprotein fluorescence ( Figure 5c ). A similar effect was observed after application of 1 mol/L 11,12-EET (Figure 5c ). The effects of 14,15-EET and 11,12-EET were rapid and lasted up to 10 minutes (see online Movie, shown only for 11,12-EET, and available in the online data supplement). These findings indicate that CYP2J2-derived eicosanoids activate mitoK ATP . Together with the inhibitor studies, these data suggest that mitoK ATP activation is one mechanism for improved postischemic functional recovery in CYP2J2 Tr mice.
Role of p42/p44: MAPK Activation in Postischemic Functional Recovery
To determine whether the MAPK signaling pathway was involved in the cardioprotective mechanism, we examined the phosphorylation status of p42/p44 MAPK in WT and CYP2J2 Tr hearts at baseline, during ischemia, and during reperfusion. There were no significant differences in the expression of phospho-p42/p44 MAPK between WT and CYP2J2 Tr hearts under basal conditions or during ischemia (Figure 6a ). Interestingly, expression of phospho-p42/p44 MAPK was significantly higher in CYP2J2 Tr hearts compared with WT hearts at 10 minutes and 40 minutes of reperfusion (Figure 6a) . Likewise, the ratio of phospho-p42/ p44 MAPK to total p42/p44 MAPK expression was significantly greater in CYP2J2 Tr hearts than in WT hearts during reperfusion (Figure 6b ). Activation of p42/p44 MAPK has been proposed to occur downstream of mitoK ATP opening 27 ; hence, we examined whether inhibition of mitoK ATP affects p42/p44 MAPK activation in our model. Notably, administration of 5-HD before ischemia failed to abolish the enhanced phosphorylation of p42/p44 MAPK in CYP2J2 Tr hearts during reperfusion (Figure 6b ). To determine whether activation of the p42/p44 MAPK pathway was required for CYP2J2-mediated cardioprotection in CYP2J2 Tr hearts, we administered the MEK inhibitor PD98059 during the reperfusion period and examined the effect on LVDP recovery. Importantly, treatment with PD98059 had minimal effect on LVDP recovery in WT hearts but completely abolished the improved postischemic recovery of LVDP in CYP2J2 Tr hearts (Figure 6c ). Thus, percent LVDP recovery was comparable in the two genotypes after treatment with PD98059. Together, these data suggest that activation of p42/p44 MAPK during reperfusion is another mechanism for improved postischemic functional recovery in CYP2J2 Tr mice.
Discussion
There has been considerable controversy in the literature regarding the functional significance of P450s in the heart. Some studies have focused on the role of these enzymes in the cardiac metabolism of drugs and xenochemicals. 2 The discovery of CYP2J2 as a primarily cardiac P450 active in the epoxidation of AA to EETs, 4 together with recent studies documenting that these P450-derived eicosanoids can affect cardiomyocyte function in vitro, 3, [13] [14] [15] [16] [17] 28 has led to the hypothesis that this enzyme may also have important endogenous functions in the heart. However, the lack of specific pharmacological tools to manipulate this pathway in vivo and the absence of an animal model to study the effects of altered P450 expression/activity on cardiac function has limited progress in this area. Moreover, studies on the biological effects of P450 metabolites in the heart have often produced conflicting results. For example, EETs are reported to have both positive 16, 17 and negative 28 inotropic effects in the heart under basal conditions. After ischemia/reperfusion, EETs are reported to have both cardioprotective 3 and cardiodepressant effects. 17 In light of these controversies, we developed a transgenic model to study the effects of CYP2J2 overexpression on cardiac function. Our major finding is that the CYP2J2 transgenic mice have normal heart anatomy and basal contractile function, but exhibit improved postischemic recovery of left ventricular function. Given that EET biosynthesis is enhanced in stenosed coronary arteries 8 and during cardiac ischemia/reperfusion injury, 7 these findings may also have important therapeutic implications. How does CYP2J2 overexpression produce beneficial cardiac effects after ischemia? To address this question, we first examined fatty acid metabolism in CYP2J2 Tr and WT hearts. Microsomes from CYP2J2 Tr hearts had increased AA epoxygenase activity compared with WT hearts, indicating increased capacity for cardiac EET biosynthesis with CYP2J2 overexpression. Moreover, isolated CYP2J2 Tr cardiomyocytes released more DHETs into culture media than did WT cardiomyocytes. In contrast, there were no significant differences between the two genotypes in the levels of LA metabolites released. These data suggest that the preferred substrate for CYP2J2 in the cardiomyocyte is AA rather than LA. Next, we examined the effect of a selective P450 epoxygenase inhibitor on postischemic recovery of contractile function. We found that MS-PPOH caused a small but significant reduction in postischemic LVDP recovery in WT mice, suggesting a role for P450 epoxygenase metabolites in mediating cardioprotection under normal conditions. Importantly, MS-PPOH completely abolished the improved postischemic LVDP recovery in CYP2J2 Tr mice, further suggesting that the cardioprotective effects of CYP2J2 overexpression are mediated by a P450 epoxygenase metabolite.
Various cardioprotective mechanisms have been proposed to explain enhanced functional recovery after ischemia. Among these, significant interest has focused on the role of K ATP . Two pharmacologically distinct K ATP types have been identified in cardiomyocytes, sarcK ATP and mitoK ATP . 29 SarcK ATP is activated during cardiac ischemia when cytoplasmic ATP is depleted and affects membrane excitability. Activation leads to shortening of the cardiac action potential and reduced intracellular calcium overload. 30, 31 Several sarcK ATP openers produce beneficial effects on the myocardium in animal models of ischemia, and several sarcK ATP inhibitors block ischemic preconditioning. 30, 31 Structurally, cardiac sarcK ATP is composed of an octomeric complex of two types of subunits (Kir6.2 and SUR2A). The EETs have been shown to be potent activators of sarcK ATP by reducing channel sensitivity to ATP; however, the exact site on the channel that interacts with EETs remains enigmatic. 13, 14 Although the precise molecular composition of mitoK ATP remains unknown, preliminary studies suggest the presence of a multiprotein complex containing succinate dehydrogenase. 32 Importantly, recent pharmacological data indicate that selective activation of mitoK ATP confers cardioprotection after ischemia 25, 26, 30, 31 ; however, a role for P450 epoxygenase metabolites in this process has not been investigated. In this regard, we observed that the beneficial effects of CYP2J2 overexpression are abolished by 5-HD, which is selective for mitoK ATP . 29 Interestingly, we also demonstrated increased flavoprotein fluorescence, a marker of mitochondrial redox status, 25 in CYP2J2 Tr cardiomyocytes consistent with enhanced mitoK ATP activation with CYP2J2 overexpression. Moreover, treatment of WT cardiomyocytes with EETs increased flavoprotein fluorescence. Taken together, these data suggest that one mechanism for the cardioprotective effects of CYP2J2 overexpression is activation of mitoK ATP . Although the precise pathways by which mitoK ATP activation confers cardioprotection remain unknown, potentially beneficial consequences of opening mitoK ATP include depolarization of the intramitochondrial membrane, transient swelling of the intramitochondrial space, enhanced respiration via the electron transport chain, reduced mitochondrial calcium overload, and altered production of reactive oxygen species. 26, 30, 31 Activation of p42/p44 MAPK has also been proposed to be cardioprotective after ischemia/reperfusion, although the precise mechanisms whereby p42/p44 MAPK activation confers cardioprotection remain unknown. 33, 34 Recent studies demonstrate that EETs activate the MAPK pathway in endothelial and vascular smooth muscle cells. 11, 12 The data presented herein demonstrate that p42/p44 MAPK activation is enhanced in CYP2J2 Tr hearts during reperfusion. We cannot rule out the possibility that at least some of the differences in phosphorylation of p42/p44 MAPK between CYP2J2 Tr and WT hearts during reperfusion were a result of protection rather than a cause of protection; however, inhibition of the MAPK pathway with a MEK inhibitor administered during reperfusion abolished the improved postischemic functional recovery in the CYP2J2 Tr animals. Together, these data suggest that another component of the cardioprotective mechanism in the CYP2J2 Tr mice involves activation of p42/p44 MAPK. We observed rapid activation of p42/p44 MAPK during early reperfusion in CYP2J2 Tr hearts, indicating that it occurred in response to the ischemic event. This is consistent with a recent report by Hausenloy and coworkers 35 showing that activation of p42/p44 MAPK at reperfusion is essential for preconditioning-induced protection. In contrast, mitoK ATP activation was enhanced before ischemia in CYP2J2 Tr hearts. Gross and coworkers 27 recently proposed that activation of p42/p44 MAPK occurs downstream of mitoK ATP opening. However, inhibition of mitoK ATP by 5-HD did not eliminate the differences in phosphorylation status of p42/p44 MAPK between CYP2J2 Tr and WT hearts. This suggests that the cardioprotective effect observed in the CYP2J2 Tr mice involves a parallel cascade of events involving both mitoK ATP and p42/p44 MAPK. The fact that inhibitors of either pathway completely abolish the improved postischemic functional recovery in CYP2J2 Tr mice suggest that activation of both are required for CYP2J2-mediated cardioprotection to occur. Figure 7 illustrates a schematic of the proposed mechanisms of cardioprotection in CYP2J2 Tr mice.
In summary, we used the ␣MHC promoter to overexpress human CYP2J2 in mouse heart. CYP2J2 Tr mice have normal basal heart anatomy and function, but exhibit improved postischemic recovery of left ventricular function. Moreover, our data suggest that the mechanism for the improved postischemic recovery in CYP2J2 Tr mice involves activation of mitoK ATP and p42/p44 MAPK. These studies are the first to document an endogenous role for this enzyme system in the heart and may have implications for the treatment of ischemic heart disease. but not with non-CYP2J P450s. Immunohistochemical staining of formalin-fixed, paraffinembedded heart tissue sections was performed as described. Transthoracic Echocardiography, Assessment of Heart Anatomy. Two-dimensional guided M-mode echocardiography was performed using an HDI 5000 echocardiograph as described. 7 CYP2J2 Tr mice (male/female, 25-30g, 4-6mo) and WT littermate controls were then sacrificed, and hearts removed, dissected, and weighed. Hearts were fixed in 10% neutral buffered formalin, processed routinely, embedded in paraffin, sectioned (5-6µm), and stained with hematoxylin/eosin for histological examination.
Isolated-Perfused Hearts. Hearts were perfused in the Langendorff mode as described. 
